Physician profile
Wenlang Xia
NPI 1578508693
$2,077.84
in general payments reported to CMS, 2019-2025
17 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $257 · 2021: $216 · 2022: $195 · 2023: $65.24 · 2024: $229 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $628.71 | 2019-2022 | |
| Ucb, INC. | $289.13 | 2024-2025 | Fintepla, Briviact |
| Eisai INC. | $232.29 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $205.72 | 2022-2025 | |
| Sk Life Science, INC. | $153.14 | 2020-2024 | |
| Livanova USA, INC. | $145.99 | 2021 | |
| Corium, LLC | $86.73 | 2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $67.15 | 2025 | Jornay Pm |
| Greenwich Biosciences, INC. | $51.71 | 2019-2021 | |
| Chiesi USA, INC. | $47.15 | 2020 | |
| Neurelis, INC. | $37.77 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $33.31 | 2023 | Daybue |
| Aprecia Pharmaceuticals, LLC | $26.54 | 2020-2022 | |
| Inspire Medical Systems, INC. | $24.59 | 2025 | Inspire |
| Immedica Pharma US, INC. | $16.84 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $15.97 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wenlang Xia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.